

## Greg A. Johnson

[greg@cagleyjohnson.com](mailto:greg@cagleyjohnson.com) | 250-516-3153  
[linkedin.com/in/johnsongreg](https://www.linkedin.com/in/johnsongreg) | [cagleyjohnson.com](http://cagleyjohnson.com)  
Victoria, BC, Canada

---

### Professional Summary

Senior Executive with over 30 years of progressive leadership experience in biotechnology, clinical research, and pharmaceutical operations. Expertise spans strategic planning, program and project management, vendor oversight, operations leadership, regulatory compliance, and implementation of computerized systems in clinical environments. Proven ability to lead cross-functional teams, manage global portfolios, and guide corporate strategy. Known for effective communication, decision-making, and stakeholder engagement, with extensive international experience in the US, Canada, UK, and Germany.

---

### Core Competencies

- Clinical Program Management
- Strategic Operations Leadership
- Board and Executive Collaboration
- Mergers & Acquisitions Due Diligence
- Vendor and CRO Management
- Financial Oversight
- Alliance Management

---

### Professional Experience

#### **Cagley Johnson Consulting Inc. | Principal Consultant**

*Jun 2011 - Present | Victoria, BC, Canada*

Provide fractional executive, program management, and strategic consulting services to biotech, pharma, and CRO clients.

*Select Engagements:*

- **Myellama Therapeutics** | Canada | Fractional CFO
- **EdEHR** | Canada | Strategic Advisor
- **Kintara Therapeutics** | Canada/USA | Acting Head of Operations
- **Rediscovery Life Sciences** | USA | Phase 2 Drug Development Program Leadership
- **MedGenesis Therapeutix** | Canada | Strategic Consulting, Project Management, and IT Support
- **BioForum** | Israel/USA | Strategic Advice and Business Development Support
- **Vivifi Biotech** | UK | Strategic Consulting

---

**MedGenesis Therapeutix Inc.**

*Victoria, BC, Canada*

**Member Board of Directors**

*Apr 2019 - Aug 2024*

**President and Chief Financial Officer**

*Oct 2012 - Mar 2017*

- Chaired Executive Committee, developed corporate strategy and annual operational plans
- Oversaw all finance functions including budgeting, forecasting, cash flow, and investment strategy
- Served as primary liaison to board, shareholders, and external stakeholders

Key Achievements:

- Negotiated Option and License Agreement for MedGenesis' lead molecule with Pfizer
- Served as Alliance Manager for MedGenesis/Pfizer Joint Steering Committee

**Chief Operating Officer / Senior Vice President of Operations**

*Mar 2007 - Sep 2012*

- Provided program leadership and project management for product development including non-clinical, technical operations, clinical operations, quality assurance, and alliance management
- Negotiated clinical collaborations and licensing agreements
- Directed CRO engagement and clinical trial oversight

Key Achievements:

- Negotiated three-way License Agreement with Amgen and Biovail to acquire MedGenesis' lead molecule
- Negotiated termination of agreement with Biovail after their acquisition by Valeant
- Negotiated collaboration agreement with North Bristol Trust for investigator initiated study for lead molecule

---

**PRA International**

*Various Global Locations*

**Vice President of Operations, Americas**

*Jan 2007 - Feb 2007*

- P&L responsibility across US, Canada, and Latin America

**Vice President of Global Data Management**

*May 2006 - Dec 2006 (USA) | Jun 2004 - Apr 2006 (Canada)*

- P&L responsibility for 300-person global data management organization
- Served on Corporate Leadership Team

Key Accomplishments

- Oversaw successful implementation of new EDC-based data management system and retirement of legacy system
- Led successful centralization of global data management services to four offices
- Established a data management center in Pune, India
- President's Award winner in 2004

**Vice President of Operations, Canada**

*Jul 2002 - May 2004*

- P&L responsibility for Canadian Trial Management operations
- Served on Corporate Leadership Team

Key Accomplishments

- Led successful operations integration of CroMedica acquisition
- President's Award winner in 2002

## **Director of Product Management**

*Mar 2001 - Jun 2002*

- Responsible for developing product methodologies, process documents, reports, and other standard infrastructure for functional operating groups
- Responsible for implementing, maintaining, upgrading and retiring computerized systems for functional operating groups
- Served on Corporate Leadership Team

### Key Accomplishments

- Successfully implemented global data management system and retired multiple legacy data management systems
- Oversaw Y2K mitigation efforts for data management systems
- Oversaw successful implementation of global system for document imaging
- Led Product Management group in laying groundwork for company to eventually establish ISO 9000 Quality Management certification
- Participated in due diligence and integration activities for multiple international acquisitions
- President's Award winner in 2001

## **Earlier Roles**

*(1992–2001)*

- Product Director (USA)
- Senior Systems Program Manager (USA)
- Manager, International Data Centre (UK)
- Supervisor IT / Clinical Data Services (Germany)

---

## **Education**

- **Master of Science (MSc), Clinical Research**  
Liverpool John Moores University | 2000  
Graduated with Distinction | Best Student Award

---

## **Certifications**

- **Fellow, Institute of Clinical Research (FICR)**  
Institute of Clinical Research  
Jan 2006

- **Project Management Professional (PMP)**  
Project Management Institute (PMI)  
May 2001  
Credential ID: 33205
- **Corporate Governance: Maximize Your Effectiveness in the Boardroom Certification**  
Wharton Executive Education  
Oct 2022  
Credential ID: 61040616
- **IP Certification – Level 1**  
New Ventures BC  
Mar 2025
- **mRNAs as Medicines Certificate**  
Moderna  
Sep 2024  
Credential ID: DET5YYW7UD8T
- **MBTI® Certified Practitioner**  
Center for Applications of Psychological Type, Inc.  
May 2011
- **Indigenous Canada Certificate**  
University of Alberta  
Nov 2020  
Credential ID: JDGSABFMP2VN
- **Zentrale Mittelstufenprüfung**  
Goethe-Institut e.V.  
Jun 1996

---

## Languages

- English - Native
- German - Fluent (previously CEFR C1, currently rusty)

---

## Publications

Guo, C, Yang, Q, Deng, M, Qiu, X, Wu, S, Du, X, Sai, K, Dai, Z, Chen, Z, Zhang, J, Lin, F, Ke, C, Xi, S, Hu, W, Zhou, Z, Li, J, Cao, X, Liao, Y, Lv, Y, Brown, D, Langlands, J, Johnson, GA, Bacha, J, Kwan, C, Kanekal, S, Schwartz, R, Chen, Z-P. "[VAL-083 is effective in patients with newly-diagnosed MGMT-unmethylated glioblastoma: report of phase II study.](#)" Discov Onc 17, 104 (2026).

Guo, C, Yang, Q, Li, J, Wu, S, Deng, M, Du, X, Sai, K, Jiang, X, Chen, Z, Zhang, J, Lin, F, Wang, J, Chen, Y, Ke, C, Zhang, X, Ju, X, Mou, Y, Bacha, J, Steino, A, Kanekal, S, Kwan, C, **Johnson, GA**, Schwartz, R, Langlands, J, Brown, D, Chen, Z-P. "[Phase 2 clinical trial of VAL 083 as first line treatment in newly-diagnosed MGMT unmethylated glioblastoma multiforme \(GBM\): Halfway report.](#)" Glioma 2020; 2:167-73.

Whone, AL, Boca, M, Luz, M, Woolley, M, Mooney, L, Dharia, S, Broadfoot, J, Cronin, D, Schroers, C, Barua, NU, Longpre, L, Barclay, CL, Boiko, C, **Johnson, GA**, Fibiger, HC, Harrison, R, Lewis, O, Pritchard, G, Howell, M, Irving, C, Johnson, D, Kinch, S, Marshall, C, Lawrence, AD, Blinder, S, Sossi, V, Stoessl, AJ, Skinner, P, Mohr, E, Gill, SS. "[Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease.](#)" Journal of Parkinson's Disease 2019; 1–13.

Whone, A, Luz, M, Boca, M, Woolley, M, Mooney, L, Dharia, S, Broadfoot, J, Cronin, D, Schroers, C, Barua, NU, Longpre, L, Barclay, CL, Boiko, C, **Johnson, GA**, Fibiger, HC, Harrison, R, Lewis, O, Pritchard, G, Howell, M, Irving, C, Johnson, D, Kinch, S, Marshall, C, Lawrence, AD, Blinder, S, Sossi, V, Stoessl, AJ, Skinner, P, Mohr, E, Gill, SS. "[Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease.](#)" Brain 2019; 142:512–525.

Grahn, AY, Bankiewicz, KS, Dugich-Djordjevic, M, Bringas, JR, Hadaczek, P, **Johnson, GA**, Eastman, S and Luz, M. "[Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience.](#)" J Neurooncol 2009; 95:185–197.

Walsh, WM, and **Johnson, GA**. "[Validation: Never an Endpoint – A Systems Development Life Cycle Approach to Good Clinical Practice.](#)" Drug Information Journal 2001; 35:809-817.

---

## Posters

Guo, C-c, Yang, Q-y, Li, J-w, Wu, S-x, Deng, M, Xi, S, Liao, Y, Chen, J-G, Wang, H-r, Bacha, J, Kanekal, S, Kwan, C, **Johnson, GA**, Schwartz, R, Langlands, J, Brown, D, Chen, Z-p. "Phase 2 Study of VAL-083 and Radiotherapy in Newly Diagnosed MGMT-unmethylated GBM: Case Study Reports" presented at the European Association of Neuro-Oncology (EANO 2023), September 2023.

Guo, C-c, Yang, Q-y, Li, J-w, Wu, S-x, Chen, J-G, Wang, H-r, Bacha, J, Kanekal, S, Kwan, C, **Johnson, GA**, Schwartz, R, Langlands, J, Brown, D, Chen, Z-p. "Phase 2 Study of VAL-083 and Radiotherapy in Newly Diagnosed MGMT-unmethylated GBM" presented at the Society for Neuro-Oncology Annual Meeting, November 2022.

Chen, Z-p, Guo, C-c, Yang, Q-y, Li, J-w, Wu, S-x, **Johnson, GA**, Langlands, J, Kwan, C, Kanekal, S, Schwartz, R, Bacha, J, Steino, A, Brown, D. "Phase 2 clinical trial of dianhydrogalactitol (VAL-083) in patients with newly diagnosed MGMT-unmethylated GBM" presented at the Society for Neuro-Oncology Annual Meeting, November 2021.

O'Brien, B, Penas-Prado, M, Kamiya-Matsuoka, C, Weathers, S-P, Yung, A, Loghin, M, Harrison, R, Majd, N, Knight, S, Bacha, J, Brown, D, **Johnson, GA**, Langlands, J, Schwartz, R, Kanekal, S, Steino, A, Lopez, L, DeGroot, J. " Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the adjuvant or recurrent setting" presented at the Society for Neuro-Oncology Annual Meeting, November 2021.

O'Brien, BJ, Kamiya-Matsuoka, C, Weathers, S-P, Yung, WKA, Loghin, M, Harrison, R, Majd, N, Knight, S, Liu, D, Bacha, JA, Brown, DM, Steino, A, **Johnson, GA**, Kanekal, S, Langlands, J, Lopez, LM, Schwartz, R, Penas-Prado, M, De Groot, J. "Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the adjuvant or recurrent setting" presented at the AACR Annual Meeting 2021, Virtual Meeting, April 2021.

Chen, Z-p, Guo, C, Yang, Q-y, Li, J-w, Wu, S-x, **Johnson, GA**, Langlands, J, Kwan, C, Kanekal, S, Schwartz, R, Bacha, J, Steino, A, Brown, D. "Phase 2 clinical trial of dianhydrogalactitol (VAL-083) in patients with newly diagnosed MGMT-unmethylated GBM" presented at the AACR Annual Meeting 2021, Virtual Meeting, April 2021.

Chen, Z-p, Guo, C-c, Yang, Q-y, Li, J-w, Wu, S-x, Bacha, J, **Johnson, GA**, Langlands, J, Kwan, C, Kanekal, S, Schwartz, R, Steino, A, Lopez, LM, Brown, D. "Phase 2 Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM" presented at the Society for Neuro-Oncology Virtual Conference, November 2020.

O'Brien, B, Penas-Prado, M, Kamiya-Matsuoka, C, Weathers, S-P, Yung, A, Loghin, M, Harrison, R, Majd, N, Knight, S, Bacha, J, Brown, D, **Johnson, GA**, Langlands, J, Schwartz, R, Kanekal, S, Steino, A, Lopez, L, DeGroot, J. "Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT unmetlyated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting" presented at the Society for Neuro-Oncology Virtual Conference, November 2020.

Chen, Z-p, Guo, C, Yang, Q-y, Li, J-w, Wu, S-x, **Johnson, GA**, Langlands, J, Kwan, C, Kanekal, S, Schwartz, R, Bacha, J, Steino, A, Brown, D. "Phase 2 study of dianhydrogalactitol (VAL-083) in patients with newly diagnosed, MGMT-unmethylated glioblastoma" presented at the American Association for Cancer Research Annual Meeting 2020, Virtual Annual Meeting II.

O'Brien, BJ, Kamiya-Matsuoka, C, Weathers, S-P, Yung, A, Loghin, M, Harrison, R, Majd, N, Bacha, JA, Brown, DM, Steino, A, **Johnson, GA**, Kanekal, S, Langlands, J, Lopez, LM, Schwartz, R, Penas-Prado, M, De Groot, J. "Phase 2 study of dianhydrogalactitol (VAL083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the adjuvant or recurrent setting" presented at the American Association for Cancer Research Annual Meeting 2020, Virtual Annual Meeting II.

O'Brien, B, Penas-Prado, M, Kamiya, C, Weathers, S-P, Yung, A, Loghin, M, Harrison, R, Bacha, J, Brown, D, **Johnson, GA**, Langlands, J, Schwartz, R, Kanekal, S, Lopez, L, deGroot, J. "Phase 2 Study of Dianhydrogalactitol (Val-083) In Patients with MGMT-Unmethylated, Bevacizumab-Naïve Glioblastoma in the Recurrent and Adjuvant Setting" presented at the Society of Neuro-Oncology Annual Meeting, Phoenix, November 2019.

Chen, Z-p, Guo, C, Yang, Q-y, Li, J-w, Wu, S-x, Bacha, J, **Johnson, GA**, Langlands, J, Kwan, C, Kanekal, S, Schwartz, R, Lopez, L, Brown, D. "Clinical Trial of Val-083 in Newly Diagnosed MGMT-Unmethylated GBM: Half-Way Report" presented at the Society of Neuro-Oncology Annual Meeting, Phoenix, November 2019.

O'Brien, BJ, De Groot, J, Kamiya-Matsuoka, C, Weathers, S-P, Bacha, JA, Brown, DM, Steino, A, Langlands, J, **Johnson, GA**, Schwartz, R, Kanekal, S, Lopez, LM, and Penas-Prado, M. "Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the adjuvant or recurrent setting" presented at the American Association for Cancer Research Annual Meeting, Atlanta, April 2019.

Chen, Z-p, Guo, C, Bacha, J, Langlands, J, Steino, A, Kwan, C, Kanekal, S, **Johnson, GA**, Schwartz, R, Lopez, LM, Brown, D. "Phase 2 study of dianhydrogalactitol (VAL-083) with radiation therapy in patients with newly diagnosed, MGMT-unmethylated glioblastoma" presented at the American Association for Cancer Research Annual Meeting, Atlanta, April 2019.

The GDNF Study Group. "Glial Cell Line-Derived Neurotrophic Factor (GDNF): Indication of Biologically Mediated Clinical Benefit in Parkinson's Disease After 80 Weeks of Treatment via Intermittent Intraputamenal Convection-Enhanced Delivery (CED)". [abstract]. *Mov Disord.* 2017.

The GDNF Study Group. "Randomized Parkinson's Trial of GDNF Administered via Intermittent Intraputamenal Convection-Enhanced Delivery". [abstract]. *Mov Disord.* 2017.

Luz, M, Dugich-Djordjevic, M, Bringas, JR, Hadaczek, P, **Johnson, GA**, Grahn, AY, Eastman, S, and Bankiewicz, KS. "Convection-enhanced Delivery of Nanoliposomal Topotecan and Gadodiamide in Rodent Intracranial Brain Tumor Xenografts and Normal Brain" presented at the Society of Neuro-Oncology Annual Meeting, Las Vegas, November 2008.

---

## Presentations

**Johnson, GA**, and Brown, D. "VAL-083 Development Update," presented at 4th Glioblastoma Drug Development Summit, Boston, 2023.

**Johnson, GA**. "Global Clinical Data Management and Electronic Data Capture," presented at Mahratta Chamber of Commerce Industries and Agriculture (MCCIA), Pune, India, 2006.

**Johnson, GA**. "Deployment of a Hybrid Data Management System," presented at the DIA Annual Meeting, Philadelphia, 2006.

Richards, N, and **Johnson, GA**. "Conducting True Hybrid Studies Using EDC and Paper Data Entry Together in the Same Trial," presented at EDC and Beyond: Leveraging Electronic Applications to Improve Data Accessibility for Rapid Decision Making, Las Vegas, 2006.

**Johnson, GA**. "Segways, TiVos, and Electronic Data Capture: new technology is always cool, but does it always add value?" keynote presentation at the Pharmaceutical Technology Congress, Philadelphia, 2005.

**Johnson, GA**. "Novel Processes in Support of CDM," session chair at the Annual Fall Conference of the Society for Clinical Data Management, Arlington VA, 2000.

Walsh, WM, and **Johnson, GA**. "Validation: Never an Endpoint – Implementing a Systems Development Life Cycle," presented at the DIA Workshop for Clinical Data Management, Philadelphia, 2000.

**Johnson, GA**, and Hanson, M. "Complying with New Industry Guidance on Computerized Systems Used in Clinical Trials," presented at the Annual Fall Conference of the Society for Clinical Data Management, Chicago, 1999.

**Johnson, GA**, and Hanson, M. "Conducting Vendor Audits," presented at North American Recorder Users Group, Chicago, 1999.

Newman, ML, and **Johnson, GA**. "Implementing New Technology (The Training Aspects of a New Global Data Management System)," presented at the Annual Fall Conference of the Society for Clinical Data Management, Washington, 1998.

**Johnson, GA**. "Experience with Recorder V3.1," presented at North American Recorder Users Group, Philadelphia, 1998.

Thier, E, (chair), Bridgman, A, Cummings, S, **Johnson, GA**, O'Donoghue, P, Tebbs, P, and Thomas, S. "Build versus Buy - The Challenge of New Software," panel discussion at the DIA Workshop for Clinical Data Management, Paris, 1997.

**Johnson, GA**, and Handelsman, D. "Combining Global Clinical Databases," presented at the DIA Workshop for Clinical Data Management, London, 1996.